You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Plasma Tissue Inhibitor of Metalloproteinases-1<br />
(TIMP-1) predicts survival in patients with metastatic<br />
colorectal cancer receiving irinotecan in combination<br />
with 5FU and folinic acid<br />
Nanna Møller Sørensen 1 , Per Byström 2 , Ib Jarle Christensen 3 , Åke Berglund<br />
4<br />
, Hans Jørgen Nielsen 3 , Nils Brünner 1 and Bengt Glimelius 2,4<br />
1<br />
Department of Veterinary Pathobiology, Royal Veterinary and Agricultural University,<br />
Denmark; 2 Department of Oncology, Karolinska Universitetssjukhuset, Stockholm, Sweden;<br />
3<br />
Department of Surgical Gastroenterology, Hvidovre University Hospital, Denmark;<br />
4<br />
Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden<br />
Background: At present no biomarker is in routine use for the prediction of<br />
treatment effects in metastatic colorectal cancer (mCRC) patients receiving systemic<br />
chemotherapy. TIMP-1 protects cancer cells against apoptosis. We raised the<br />
hypothesis that elevated plasma levels of TIMP-1 in mCRC patients would predict<br />
resistance to apoptosis-inducing chemotherapy. Accordingly, these patients would<br />
have a shorter survival than mCRC patients with low plasma TIMP-1 levels despite<br />
chemotherapy. The objective of the present study was to test this hypothesis.<br />
Patients and Methods: 89 patients with mCRC were included in the study. Plasma<br />
TIMP-1 was measured in samples obtained before the first cycle of chemotherapy.<br />
TIMP-1 was analysed by an ELISA that measures both uncomplexed and complexed TIMP-1.<br />
Results: Plasma TIMP-1 scored as a continuous variable on the log scale<br />
(log<br />
26l12<br />
e<br />
) was significantly associated to OS (HR=3.8, 95% CI: 2.4-6.0, p